Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines

2026-04-07 14:22:19

Gilead Sciences announced it will acquire privately held biotech firm Ouro Medicines for over $2 billion to expand its immunology pipeline. This deal includes an upfront payment of $1.68 billion in cash and up to $500 million in milestone payments, adding Ouro’s experimental antibody drug OM336 for autoimmune conditions to Gilead’s portfolio. Gilead is also in discussions with partner Galapagos to collaborate on research and development for Ouro Medicines’ assets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes